An observational study in Glaucoma, sponsored by Nantes University Hospital. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Nantes University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Glaucoma with a site in France — 10 open to participants now, 11 under way, none of them phase 3. Glaucoma · France.
Among the 54 studies in Glaucoma with a site in France, this one is the 13th largest by planned enrollment of the 16 observational ones that give a count, is one of 3 that started in 2024, is one of 16 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 47th registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →10 of the 54 studies in Glaucoma with a site in France are open now. Recruiting first, the newest first:
Hôpital Privé de la Baie · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
Hôpital Privé de la Baie · Sites in France
Ages 18+
Hôpital Privé de la Baie · Sites in France
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 100 across 385 observational studies indexed under Glaucoma.
Median enrollment 105 across the 38 interventional studies, 120 across the 16 observational. Of the 36 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 54 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 191 are open to participants now.
Nantes University Hospital has 1 study filed under Glaucoma — fewer than ten, so there is no comparison to draw.
4 of the studies in Glaucoma with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06274593Nantes University HospitalStudy of OCT Peripapillary Angiography in Patients With Advanced Glaucoma | 2027-04-27 |
| NCT07802769University Hospital, BordeauxMagnetic Resonance Imaging of Cerebral Connectivity and Volume in Neurodegeneration and Glaucoma | 2027-05 |
| NCT04129021Centre Hospitalier National d'Ophtalmologie des Quinze-VingtsHigh Resolution, High-speed Multimodal Ophthalmic Imaging | 2027-07 |
| NCT07303257Hospices Civils de LyonQuality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Glaucoma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Glaucoma is a chronic disease of the optic nerve, characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second leading cause of blindness after cataracts, and the leading cause of irreversible blindness.
To date, to our knowledge, there is no work analyzing the progression of angiographic OCT in patients with glaucoma.
The main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl).
Glaucoma is a chronic disease of the optic nerve characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second-leading cause of blindness after cataracts and the leading cause of irreversible blindness.
The pathophysiology and loss of retinal ganglion cells are partly explained by 2 main theories:
Optical coherence tomography angiography (OCTa) is a relatively new imaging method that has been on the market for around ten years.
It is a non-invasive method that provides qualitative and quantitative information on retinal vascularization and the optic nerve head. The movement of red blood cells is used as a contrast medium to differentiate blood vessels from static tissue.
In glaucoma, changes in the peripapillary vascular plexus (around the optic nerve head) can be observed and are topographically correlated with visual field and peripapillary nerve fiber deficits.
One of the challenges in monitoring glaucoma patients lies in detecting the progression of the disease with the help of various complementary examinations, including the visual field, peripapillary nerve fiber OCT (RNFL), and more recently, OCTa.
The visual field is used to detect areas of vision deficit (peripheral or sometimes central), known as scotomas, and to monitor their evolution. RNFL OCT measures the thickness of the optic nerve (in micrometers) in its various quadrants. OCTa measures vascular density, also by quadrant, around the optic nerve head.
A deterioration in any of these parameters can help guide therapeutic management by modifying medical treatment or proposing surgery to lower intraocular pressure in the affected eye.
One of the difficulties in monitoring glaucoma patients lies in detecting optic nerve thinning in patients with advanced optic nerve damage. It is now well known that at an advanced stage of the disease, measurement of optic nerve thickness on RNFL OCT can reach a "floor" effect: residual non-neuronal tissue limits the usefulness of detecting changes in neuronal tissue, and disease progression can only be detected by visual field monitoring.
Vascular density measured on OCTa appears to reach a plateau effect in a delayed manner compared with measurements obtained on peripapillary OCT (RNFL) and could enable better monitoring of disease progression in patients with advanced glaucoma.
Indeed, a new objective follow-up criterion measured with OCTa in clinical practice for patients with uninterpretable OCTrnfl would be a valuable tool for assessing the rate of glaucoma progression in these patients and thus defining the rate of monitoring and the decision to intensify treatment in the event of progression. This is all the more important as the treatments available for glaucoma are sometimes invasive (drainage devices, surgery, etc.). Assessing the benefit-risk balance therefore requires objective data for these patients.
To date, to our knowledge, there are no studies analyzing the evolution of OCT angiography in glaucoma patients.
The main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl).
Patients followed at Nantes University Hospital for advanced glaucoma (MD>10dB in visual field) who had peripapillary angiography OCT, OCTrnfl and visual field at their follow-up consultation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Peripapillary angiography (OCT) at baseline and each year during 3 year
Compare the progression of vascular density (VD) in advanced glaucoma patients.
Progression of peripapillary vascular density (VD) (in percent) per sector (8 sectors) with 3-year follow-up.
Time frame: 3 year
Compare the progression of peripapillary retinal nerve fiber (RNFL) thickness) in advanced glaucoma patients.
Progression of peripapillary nerve fiber thickness (RNFL, in µm) per sector (8 sectors) with 3-year follow-up.
Time frame: 3 year
Compare the progression of visual field in advanced glaucoma patients.
Progression of visual field deficit (in dB) by sector (8 sectors) with 3-year follow-up
Time frame: 3 year
CV-OCTrnfl correlation study and CV-OCTa correlation study on measurements made at inclusion and on measurements made during follow-up
Study of the correlation between CV-OCTrnfl and correlation between CV-OCTa (mean in µm)
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.
Of 110 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 36 months is below that.
Counting every sponsor, half of 134 studies reached it within 31 months; a quarter within 12 and three quarters within 208.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.